Genscript Biotech (HKSE:01548) Long-Term Capital Lease Obligation : HK$499 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Long-Term Capital Lease Obligation?

Genscript Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$499 Mil.

Genscript Biotech's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (HK$343 Mil) to Jun. 2023 (HK$514 Mil) but then declined from Jun. 2023 (HK$514 Mil) to Dec. 2023 (HK$499 Mil).

Genscript Biotech's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$213 Mil) to Dec. 2022 (HK$343 Mil) and increased from Dec. 2022 (HK$343 Mil) to Dec. 2023 (HK$499 Mil).

Genscript Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Genscript Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Long-Term Capital Lease Obligation Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

28.16

50.49

213.30

342.62

499.09

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial														213.30	201.21	342.62	513.94	499.09

Genscript Biotech (HKSE:01548) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Genscript Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines